Skip to main content


Full Schedule

Full Schedule

  • Monday, September 19, 2022
  • 7:30 AM – 8:45 AM CT
    Paradigm Shift: A New Appreciation for Methylphenidate in Adults with ADHD
  • 7:30 AM – 8:45 AM CT
    Telehealth as Part of the Treatment Plan for Adults with Schizophrenia on Long-acting Injectables
  • 9:00 AM – 10:15 AM CT
    Breaking Down the Barriers to Utilizing Long-Acting Injectable Antipsychotics for Schizophrenia Management
  • 9:00 AM – 10:15 AM CT
    Clinical Approach To Diagnosing And Treating Complex ADHD: Focus Of The Triple Co-Morbidly Of ADHD, Anxiety, And Mood Disorders
  • 9:00 AM – 10:15 AM CT
    How to Evaluate a Stalker
  • 9:00 AM – 10:15 AM CT
    The Role of Psychiatrists in Contraception
  • 10:30 AM – 11:45 AM CT
    Clinical Considerations for Patients with Excessive Daytime Sleepiness due to Obstructive Sleep Apnea: Novel Strategies for Improved Management
  • 10:30 AM – 11:45 AM CT
    Psychedelic-assisted Psychotherapy: How is it Different from What We Already Do?
  • 10:30 AM – 11:45 AM CT
    Somatic and Pharmacological Treatments: Reducing Near-Term Suicide Risk
  • 10:30 AM – 11:45 AM CT
    State of Schizophrenia
  • 11:45 AM – 3:15 PM CT
    Exhibit Hall
  • 12:00 PM – 1:15 PM CT
    Health Disparities: How Prescription Digital Therapeutics are closing gaps in care
  • 12:00 PM – 1:15 PM CT
    How to Introduce a Long-acting Injectable With a Longer Dosing Interval for Adult Patients With Schizophrenia Into Your Practice
  • 12:00 PM – 1:15 PM CT
    Making a Difference for Patients With Tardive Dyskinesia (TD) Proactively Recognizing and Treating an Overlooked Disorder
  • 12:00 PM – 1:15 PM CT
    The Efficacy and Safety Profile of an Adjunctive Therapy for Adult Patients with Major Depressive Disorder (MDD)
  • 1:30 PM – 3:00 PM CT
    Poster Presentations in Exhibit Hall
  • 1:45 PM – 3:15 PM CT
    Long Acting Injectable (LAI) and Motivational Interviewing Workshop
  • 2:00 PM – 3:00 PM CT
    S.C.O.P.E.™ : Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement - An Interactive Digital Platform to Educate on Schizophrenia Care
  • 3:30 PM – 4:45 PM CT
    Novel CGRP Monoclonal Antibodies and CGRP Receptor Antagonists: A Recipe for Success in Migraine Prevention and Treatment
  • 3:30 PM – 4:45 PM CT
    Solving Clinical Challenges: Treatment Resistant Depression
  • 3:30 PM – 4:45 PM CT
    The Future of Psychedelic Therapy: Training a New Generation of Clinicians
  • 3:30 PM – 4:45 PM CT
    Treating Agitation: Can We Avoid Injections? Should We?
  • 5:00 PM – 6:15 PM CT
    Neuroplasticity and Its Role in MDD: New Solutions with Digital Therapeutics
  • 5:00 PM – 6:15 PM CT
    Not Getting Better!- Diagnostic Conundrums and Treatment Considerations in Mood Disorders
  • 5:00 PM – 6:15 PM CT
    Practice-friendly evaluation and treatment of pediatric mood disorders
  • 5:00 PM – 6:15 PM CT
    The Many Faces of Ketamine: Merging Biological Psychiatry and Psychedelic Medicine
  • 6:30 PM – 7:45 PM CT
    Agitation in Alzheimer’s Dementia: Progress in an Age-Old Problem
  • 6:30 PM – 7:45 PM CT
    Incorporating the Peer Perspective in Research
  • 6:30 PM – 7:45 PM CT
    Management of OCD and Co-occurring Substance Addiction.
  • 6:30 PM – 7:45 PM CT
    Symptom Management Or Symptom Elimination? What Should Be Goal Of Treatment Of Depression In Real World Clinical Practice